Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.
1. A recombinant Modified Vaccinia Ankara Virus (MVA) comprising one or more human immunodeficiency virus DNA coding sequences inserted into an intergenic region (IGR) of the viral genome, wherein the IGR is selected from the group consisting of IGRs:
001L-002L, 002L-003L, 005R-006R, 006L-007R, 007R-008L, 008L-009L, 017L-018L, 018L-019L, 019L-020L, 020L-021L, 023L-024L, 024L-025L, 025L-026L, 028R-029L, 030L-031L, 031L-032L, 032L-033L, 035L-036L, 036L-037L, 037L-038L, 039L-040L, 043L-044L, 044L-045L, 046L-047R, 049L-050L, 050L-051L, 051L-052R, 052R-053R, 053R-054R, 054R-055R, 055R-056L, 061L-062L, 064L-065L, 065L-066L, 066L-067L, 077L-078R, 078R-079R, 080R-081R, 081R-082L, 082L-083R, 085R-086R, 086R-087R, 088R-089L, 089L-090R, 092R-093L, 094L-095R, 096R-097R, 097R-098R, 101R-102R, 103R-104R, 105L-106R, 107R-108L, 108L-109L, 109L-110L, 110L-111L, 113L-114L, 114L-115L, 115L-116R, 117L-118L, 118L-119R, 122R-123L, 123L-124L, 124L-125L, 125L-126L, 133R-134R, 134R-135R, 137L-138L, 141L-142R, 143L-144R, 144R-145R, 145R-146R, 146R-147R, 147R-148R, 148R-149L, 152R-153L, 153L-154R, 154R-155R, 156R-157L, 157L-158R, 159R-160L, 160L-161R, 162R-163R, 163R-164R, 164R-165R, 165R-166R, 166R-167R, 167R-168R, 170R-171R, 173R-174R, 175R-176R, 176R-177R, 178R-179R, 179R-180R, 180R-181R, 183R-184R, 184R-185L, 185L-186R, 186R-187R, 187R-188R, 188R-189R, 189R-190R, and 192R-193R.
2. The recombinant MVA of claim 1 , wherein the IGR is 007R-008L.
3. The recombinant MVA of claim 1 , wherein the IGR is 018L-019L.
4. The recombinant MVA of claim 1 , wherein the IGR is 044L-045L.
5. The recombinant MVA of claim 1 , wherein the IGR is 064L-065L.
6. The recombinant MVA of claim 1 , wherein the IGR is 148R-149L.
7. The recombinant MVA of claim 1 , wherein the MVA comprises multiple human immunodeficiency virus DNA coding sequences inserted into multiple intergenic regions (IGR) of the viral genome.
8. The recombinant MVA of claim 1 , wherein the coding sequences are placed under the transcriptional control of one or more poxviral transcription control elements.
9. The recombinant MVA virus of claim 1 , wherein one or more of the human immunodeficiency virus DNA coding sequences is an HIV Env sequence.
10. The recombinant MVA virus of claim 8 , wherein the poxviral transcription control element is the ATI promoter.
11. The recombinant MVA virus of claim 8 , wherein the poxviral transcription control element is the p7.5 promoter.
12. An isolated host cell comprising the recombinant MVA of claim 1 , wherein the host cell is a prokaryotic cell.
13. An isolated host cell comprising the recombinant MVA of claim 1 , wherein the host cell is a eukaryotic cell.
14. The host cell of claim 13 , wherein said cell is a human cell.
15. The host cell of claim 13 , wherein said cell is a nonhuman mammalian cell.
16. The host cell of claim 13 , wherein said cell is an insect cell.
17. The host cell of claim 13 , wherein said cell is a fish cell.
18. The host cell of claim 13 , wherein said cell is a plant cell.
19. The host cell of claim 13 , wherein said cell is a fungal cell.